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Alcohol Consumption and Mortality
in Patients With Cardiovascular Disease
A Meta-Analysis
Simona Costanzo, SCD, Augusto Di Castelnuovo, SCD, Maria Benedetta Donati, MD, PHD,
Licia Iacoviello, MD, PHD, Giovanni de Gaetano, MD, PHD
Campobasso, Italy
Objectives The purpose of this study was to quantify the relation between alcohol consumption and cardiovascular and to-
tal mortality in patients with a history of cardiovascular events.
Background Regular, moderate alcohol consumption by healthy people is associated with lower cardiovascular and all-cause
mortality. No extensive meta-analysis is presently available on the possible association of alcohol consumption
with secondary events in patients with cardiovascular disease.
Methods Articles were retrieved through October 2009 by search in PubMed and EMBASE. Fifty-four publications were
identified, but only 8 were selected for our analyses, including 16,351 patients with a history of cardiovascular
disease. Secondary events were cardiovascular or all-cause mortality. All selected studies were prospective. Data
were pooled with a weighted, least-squares regression analysis of second-order fractional polynomial models.
Results The meta-analysis on cardiovascular mortality showed a J-shaped pooled curve with a significant maximal pro-
tection (average 22%) by alcohol at approximately 26 g/day. In the meta-analysis on mortality for any cause,
J-shaped pooled curves were observed in the overall analysis (average maximal protection of 18% in the range of 5 to
10 g/day) and in all subgroups according to either the type of patients or the characteristics of the studies.
Conclusions In patients with cardiovascular disease, light to moderate alcohol consumption (5 to 25 g/day) was significantly
associated with a lower incidence of cardiovascular and all-cause mortality. (J Am Coll Cardiol 2010;55:
1339–47) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.006c
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voderate, regular alcohol consumption by apparently
ealthy people is associated with lower cardiovascular mor-
idity and mortality than in abstainers (1–6). Mechanisms
upporting this include beneficial regulation of lipids and
brinolysis, decreased platelet aggregation and coagulation
actors, beneficial effects on endothelial function, and in-
ammation and insulin resistance (7–9). The proposed
echanisms of the beneficial role of drinking in moderation
n healthy people may be similarly effective in people with a
istory of cardiovascular disease (CVD).
The abuse of alcohol is unquestionably harmful
2,3,6,10); in fact, the relationship between alcohol con-
umption and ischemic cardiovascular events or all-cause
ortality in healthy people has been depicted as a J-shaped
rom the Laboratory of Genetic and Environmental Epidemiology, “RE ARTU”
esearch Laboratories, “John Paul II” Centre for High Technology Research and
ducation in Biomedical Sciences, Catholic University, Campobasso, Italy. Sup-
orted in part by grant EA0827 from the European Research Advisory Board
ERAB).c
Manuscript received November 19, 2009; revised manuscript received January 15,
010, accepted January 18, 2010.urve attributed to a dose-related combination of beneficial
nd harmful effects (1,11,12). The nonlinear J-shaped
ose-response curve supports the hazards of excess drinking,
ut also indicates the potential windows of alcohol con-
umption that may confer a net beneficial effect, at least in
erms of survival for apparently healthy subjects.
The 2006 Diet and Lifestyle Recommendations Scientific
tatement from the American Heart Association Nutrition
ommittee (13) advises: “If you consume alcohol, do so in
oderation (equivalent of no more than one drink for
omen or two drinks for men per day).” This is widely
ccepted within the scientific community, definitely when
eferring to healthy people. However, some concern has
een raised of late regarding whether it is advisable to
ncourage people to drink small amounts regularly rather
han abstain completely, especially among poor populations
nd in low-income countries where the disease burden per
nit of alcohol consumption seems to be greater (10,14).
It is fundamental to prevent ischemic recurrences in survi-
ors of primary cardiovascular events. Among the factors
ontributing to prevention, improving lifestyle and dietary
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Alcohol Consumption and Mortality in CVD Patients March 30, 2010:1339–47habits play a major role. However,
guidelines in this area (15,16) are
based on studies of apparently
healthy subjects, on only few stud-
ies in cardiovascular patients, or
both. Other recommendations
about alcohol consumption in pa-
tients with previous CVD are
based on experts’ consensus rather
than circumstantial evidence (17).
he United States Food and Drug Administration warns that
eart disease patients should stop drinking and that people
ho take aspirin regularly should not drink alcohol (18).
owever, in the 2006 American Heart Association/American
ollege of Cardiology Guidelines for Secondary Prevention
16), CVD patients are encouraged to maintain a lifestyle that
ncludes alcohol in moderation.
Several observational studies evaluated the association
etween alcohol intake and secondary events in CVD
atients (19). One meta-analysis that examined the rela-
ionship between dietary changes and mortality in patients
ith coronary artery disease reported a reduction in all-
ause mortality risk in moderate drinkers (20).
We present here the findings from 2 meta-analyses assessing
he relationship between alcohol drinking and either fatal
ardiovascular events or mortality for any cause in patients with
history of cardiovascular events. Our work extends that of
estra et al. (20) because we included more recent studies and
orrelated alcohol intake by patients with established coronary
rtery disease with cardiovascular mortality in addition to total
ortality. Moreover, current issues in epidemiology of alcohol
onsumption and health will be discussed.
ethods
earch strategy and data extraction. Articles were re-
rieved through October 2009 by searching in PubMed and
MBASE using the following key words: cardiovascular
isease or patients in combination with alcohol, wine, beer,
nd spirits and with mortality, morbidity, survival, death (as
edical Subject Heading terms or text word), supple-
ented by references from the selected articles. Fifty-four
ublications were identified. Two of us independently
eviewed them and selected 8 studies (21–28) of patients
ith a history of CVD. Studies were excluded if the
ualifying primary event was different from coronary heart
isease, AMI, or stroke; if only one category of alcohol
ntake was reported, or if it was not possible to extract
uantitative data on alcohol consumption or if they were
ultiple reports (in that case, the report with the longer
ollow-up was used) (Fig. 1).
Secondary events included cardiovascular or all-cause
ortality. As far as primary events are concerned, 7 studies
ncluded patients with previous CVD (1 stroke [24], 1
oronary heart disease [26], 5 AMI [21–23,25,28]), and 1
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CVD  cardiovascular
disease
RR  relative risk
SE  standard erroriabetic patient with a history of coronary heart disease (27) sTable 1). All selected studies were prospective (5 cohort
tudies [21,22,25–27]), and 3 were studies primarily de-
igned as randomized control trials for specific drug therapy
n CVD patients (23,24,28). Seven studies reported results
Figure 1 Flow Chart of the Selected Studies
AMI  acute myocardial infarction; CHD  coronary heart disease.eparately for all-cause and cardiovascular mortality
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March 30, 2010:1339–47 Alcohol Consumption and Mortality in CVD Patients21,23–26,28), 1 for all-cause mortality only (22), and 1 for
VD mortality only (27). With reference to alcohol con-
umption, all studies were observational. We performed 2
eta-analyses: the first included 7 studies reporting second-
ry risk of cardiovascular mortality and the second consid-
red 7 studies reporting secondary risk of mortality for any
ause (Table 1).
The size of a drink was taken as quantified in each article,
xcept in 2 American studies (23,28) where a size of 14.0 g
thanol was chosen, according to the International Center for
lcohol Policies guidelines (29). In 3 studies (22,26,27) former
rinkers were excluded formally from the reference group of
ife-long abstainers or nondrinkers, whereas in 2 studies, they
ere not (21,25) (in one of these, the authors performed a
ensitivity analysis excluding former drinkers from the refer-
nce group (21)); in the remaining 3 studies (23,24,28), no
tatement about the reference group was made (Table 1).
ata analysis. We collected the following data: 1) the
alue x of alcohol (grams per day) assigned as the midpoint
f the ranges (x was defined as 1.2 times the lower boundary
or the open-ended upper categories [30]; our results did not
hange on multiplying the lower boundary for the open-
nded upper categories by 1.0 or 1.4 or 1.6 instead of 1.2
data not shown]); 2) frequency counts, adjusted relative risk
RR), and 95% confidence intervals for each x level; and
) covariates describing the characteristics of the study.
nverse-variance–weighted methods that account for
ithin-study correlation estimates were used (30). The
odels to be fitted were selected among fractional polyno-
ial curves of the second order (31), considering power
ransformations of a continuous variable restricted to a
redefined set of exponents (32). The regression models
ere log(RR|x)  1x
p  2x
q and p and q were selected
ut of the set (2, 1, 0.5, 0, 0.5, 1, 2), after fitting
ultiple models. When p  0, xp is replaced by log(x), and
hen p  q, the model becomes log(RR|x)  1x
p 
2x
qlog(x) (32). The best fit for p and q was defined as that
ith the highest likelihood.
To consider differences between studies as a further
ource of random variability, an additional component of
haracteristics of the 8 Studies Included in 1 or Both Meta-AnalysTable 1 Characteristics of the 8 Studies Included in 1 or Both
First Author, Year (Ref. #) Country
Follow-Up
(yrs) n
Primary
Event
Janszky et al., 2008 (21) Sweden 8.6 1,332 AMI
Masunaga et al., 2006 (22) Japan 1.1 3,845 AMI
Aguilar et al., 2004 (23) USA 3.5 2,036 AMI
Jackson et al., 2003 (24) USA 4.5 1,320 Stroke
Mukamal et al., 2001 (25) USA 3.8 1,913 AMI
Shaper et al., 2000 (26) England 12.8 596 CHD
Valmadrid et al., 1999 (27) USA 12.3 266 CHD
Muntwyler et al., 1998 (28) USA 5.0 5,356 AMI
Exclusion of ex-drinkers in reference group in sensitivity analysis.
A few days after the primary event; AC-M all-causemortality; AMI acutemyocardial infarcti
isease; CV-M  cardiovascular mortality.he variance was added in weighing each observation (ran- mom effects). When there was heterogeneity, that is, when
andom and fixed solutions significantly differed, the anal-
ses were carried out excluding one study at a time, and the
eviances of random and fixed models were examined; a
tudy was eliminated if its inclusion in the meta-analysis
everely increased the deviances. Comparison of 2 hierar-
hical models was tested by the likelihood ratio test includ-
ng or not in the models the interaction terms between the
ovariates (sex, type of primary event, design of the refer-
nce group) and alcohol intake (volume). Estimations of the
etrics “maximal protection” and “reversion point” from the
ooled dose-response curves were used to help data inter-
retation. Imprecision in the evaluation of these metrics
rom fitting of data is unavoidable; thus, point estimates of
hese parameters should not be emphasized. Pairwise con-
rasts were adjusted following the method of Sidak. All
nalyses were carried out using an SAS macro (SAS version
.1.3 for Windows, SAS Institute, Cary, North Carolina) (32).
The hypothesis that publication bias may affect the validity
f the estimates was tested by a funnel-plot–based approach. A
imple test of asymmetry of the funnel plot was used according
o the method proposed by Egger et al. (33). The symmetry of
unnel plots was measured applying the following linear model:
Rj/se(RRj)    1/se(RRj), where RRj/se(RRj) is the
tandard normal deviate (relative risk divided by its standard
rror), 1/se(RRj) is the precision of the estimate, and  and 
re the unknown parameters of the model.
The basic idea of this method is that, in the absence of
ublication bias and therefore in the presence of a symmet-
ic funnel plot, the points will scatter about a line that runs
hrough the origin. In this situation, an estimate of the
arameter  would be found nearly equal to 0.
esults
lcohol intake and cardiovascular mortality in CVD
atients. From 7 studies (21,23–28) comprising 12,819
VD patients (Tables 1, 2), we obtained 7 dose-response–
ndependent relationships for alcohol and cardiovascular
-Analyses
econdary
Event
When
Questionnaire
Administered
Former Drinkers
in Reference
Group Sex
Meta-Analysis
Inclusion
-M, AC-M A Yes* M, F Both
-M A No M Total mortality
-M, AC-M B Not stated M, F Both
-M, AC-M B Not stated M Both
-M, AC-M A Yes M, F Both
-M, AC-M B No M Both
-M B No M, F CVD mortality
-M, AC-M B Not stated M Both
more than 2months after the primary event; CHD coronary heart disease; CVD cardiovascularesMeta
S
CV
AC
CV
CV
CV
CV
CV
CVortality. Symmetric funnel plots ( 0) were obtained for
a
p
a
s
i
a
0

3
f
h
fi
a
s
q
t
c
n
(
e
fi
a
(
(
t
v
(
o
A
p
t
d
a
p
(
m
r
e
d
c
e
f
o
a
p
r
i
w
t
p
i
c
s
r
u
p
m
l
t
D
T
a
C
* s no lon
1342 Costanzo et al. JACC Vol. 55, No. 13, 2010
Alcohol Consumption and Mortality in CVD Patients March 30, 2010:1339–47ll the categories of alcohol intake, showing the absence of
ublication bias (Fig. 2A).
The overall relationship between cardiovascular mortality
nd alcohol intake was interpreted as a J-shaped curve (Fig. 3),
howing a protective effect (average 22%) that was maximal
n the range of 5 to 10 g/day and still was significant up to
pproximately 26 g/day (Table 2 and Fig. 3, fixed model).
The best-fitting model was obtained when p  q 
.5, corresponding to the model: logRR  1x 
2x*log(x), for both the fixed and random models (Fig.
). The deviances of fixed and random effects models fell
rom 22.30 to 12.60 (p  0.002 for difference), suggesting
eterogeneity among studies. The fitted parameters for the
xed model were 1  0.181 (SE  0.058; p  0.001)
nd 2  0.044 (SE  0.021; p  0.017) (Table 2). In
ubsequent analyses, using a fixed effects model with p 
 0.5, we explored the possible role of study characteris-
ics in explaining the interstudy heterogeneity.
Three studies reported results on men only and 4 in-
luded both men and women; the subgroup analysis showed
o difference between the 2 groups of studies (p  0.90)
Table 2). Pooled analyses of 3 studies (21,26,28) that
xcluded former drinkers from the reference category con-
rmed the protection of moderate alcohol consumption
gainst cardiovascular mortality (Table 2).
Alcohol intake questionnaires were administered quite late
more than 2 months) after the qualifying event in 5 studies
23,24,26–28), but after only a few days in 2 studies (21,25). In
he first group of studies, a J-curve was confirmed, with a shape
ery similar to that obtained using all studies on CVD patients
Table 2). Similar results were found considering only studies
n patients with a previous AMI (Table 2).
lcohol intake and mortality for any cause in CVD
atients. Seven studies (21–26,28), comprising 16,398 pa-
ients with previous CVD (Tables 1 and 2), provided 9
haracteristics and Results of the Best-Fitting Models: Meta-AnalyTable 2 Characteristics and Results of the Best-Fitting Models
Subgroup
No. of
Curves n
Maximal Protect
% (95% CI) g/
All studies
Random model 7 12,819 26 (13–37)
Fixed model 7 12,819 22 (13–30)
Sex
Men 3 7,272 21 (11–31) 1
Both sexes 4 5,547 25 (9–38)
Type of primary event
AMI 4 10,637 19 (8–28) 1
Type of reference group
Without former drinkers 3 2,110 47 (27–62)
Alcohol intake questionnaire administration
More than 2 months after the primary
event
5 9,574 21 (11–29)
The reversion point is defined as the dose of alcohol at which protection against total mortality i
AMI  acute myocardial infarction; CI  confidence interval.ose-response independent relationships for alcohol intake mnd mortality from any cause. In this meta-analysis, too,
ublication bias was absent (Fig. 2B).
Two studies reported results separately for 2 age groups
22,28), and each contributed with 2 curves. The best-fitting
odel was obtained when p  q  0.5 for both the fixed and
andom models (Table 3). Deviances of fixed and random
ffects models fell from 119.63 to 20.72 (p  0.001 for
ifference), indicating heterogeneity among studies. After ex-
lusion of a Japanese study (22), deviances of fixed and random
ffects models fell to 30.90 and 12.29, respectively (p  0.001
or difference). In both the random and fixed-effects models, an
verall J-shaped curve was obtained from the remaining 7
djusted dose-response curves (Table 3, Fig. 4); the maximal
rotection was 20% and 18% in a range of 5 to 10 g/day in a
andom and fixed-effects model, respectively. Four studies
ncluded men only and 3 studies included both men and
omen; the subgroup analysis showed no difference between
hese 2 groups of studies (p  0.47) (Table 3).
Similar results were found considering only studies of
atients with a previous AMI (Table 3). Four studies gathered
nformation on alcohol consumption late after the qualifying
ardiovascular event (2 months) (23,24,26,28). In these
tudies, a J-shape curve was confirmed, with 24% maximal risk
eduction at approximately 8 g/day and significant protection
p to approximately 24 g/day (Table 3). Six studies (12,553
atients) reported data both for cardiovascular and all-cause
ortality (21,23–26,28). The 2 J-shaped curves overlapped at
ight consumption (6 to 12 g/day), showing maximal protec-
ion of approximately 20% (Fig. 5).
iscussion
he main novelty of the findings presented here is that—as in
pparently healthy subjects—in CVD patients too, light to
f Alcohol Intake and Cardiovascular Mortalityta-Analysis of Alcohol Intake and Cardiovascular Mortality
Reversion
Point*
(g/day)
Parameters of the Best-Fitted Model 
LogRR  1x  2x*log(x) p Value
for
Difference1 (SE) p Value 2 (SE) p Value
0.002
24 –0.215 (0.088) 0.008 0.052 (0.031) 0.047
26 –0.181 (0.058)  0.001 0.044 (0.021) 0.017
0.90
23 –0.161 (0.072) 0.013 0.036 (0.026) 0.08
18 –0.219 (0.098) 0.013 0.058 (0.035) 0.049
24 –0.136 (0.065) 0.018 0.031 (0.023) 0.092
18 –0.538 (0.165) 0.019 0.157 (0.059) 0.077
24 –0.158 (0.067) 0.009 0.037 (0.025) 0.067
ger statistically significant at the 95% confidence level.sis o: Me
ion
day
8
8
3
8
2
5oderate drinking (5 to 15 g/day of alcohol) is associated
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March 30, 2010:1339–47 Alcohol Consumption and Mortality in CVD Patientsith significant cardiovascular or all-cause mortality risk
eduction, or both. In both our meta-analyses, a signifi-
ant association with reduced risk was found up to 25
/day of alcohol. The J-shaped relationship between
lcohol intake and total mortality was comparable with
hat previously reported in apparently healthy individuals
11) and can be explained as a dose-related combination
f both beneficial and harmful effects. If alcohol intake
ithin a relatively large range is inversely related to
VD, increasing alcohol consumption is reportedly as-
Figure 2 Funnel Plots of the Selected Studies for Both Meta-An
Funnel plots for different alcohol intake categories (0.5 to 5.2 g/day, 5.2 to 12.5
(A) Alcohol intake and cardiovascular mortality in cardiovascular disease (CVD) paociated with an increasing risk of certain cancers, cir- chosis, and death from accidents (2,11). When alcohol
se was recorded somewhat late after diagnosis of the
rimary event (more than 2 months), probably reflecting
he real intake of alcohol before a secondary event, the
rotective effect of moderate alcohol consumption was
onfirmed by both meta-analyses.
From the 6 studies that reported data on both cardiovas-
ular and all-cause mortality, 2 similar dose-response curves
ere obtained (Fig. 5). Most likely, as in patients with
revious CVD, the main cause of death is a secondary fatal
es
12.5 to 25 g/day, 25 to 35 g/day) for both meta-analyses.
(B) Alcohol intake and mortality for any cause in CVD patients.alys
g/day,
tients.ardiovascular event; the reduction in cardiovascular risk by
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Alcohol Consumption and Mortality in CVD Patients March 30, 2010:1339–47oderate alcohol consumption would prevail over the less
requent noncardiovascular fatal events.
In patients with CVD, the potential interactions with
lcohol have been investigated mainly for antiplatelet or oral
nticoagulant drugs (34). Alcohol and medications interact
n a variety of situations; absorption, distribution, or me-
Figure 3 Alcohol Consumption in Relation to Cardiovascular M
Pooled curves of relative risk of cardiovascular mortality and alcohol intake, extracted
and random (dotted lines) models. RR  relative risk; 95% CI–  lower value of c
haracteristics and Results of the Best-Fitting Models: Meta-AnalyTable 3 Characteristics and Results of the Best-Fitting Models
Subgroup
No. of
Curves n
Maximal Protect
% (95% CI) g/
All studies
Random model 9 16,398 22 (2–39) 2
Fixed model 9 16,398 24 (16–31) 2
Selected studies†
Random model 7 12,553 20 (9–30) 7
Fixed model 7 12,553 18 (10–25) 7
Sex†
Men 4 7,272 18 (8–28) 5
Both sexes 3 5,281 21 (8–33) 12
Type of primary event†
AMI 5 10,637 22 (16–30) 12
Alcohol intake questionnaire administration†
More than 2 months after the primary
event
5 9,308 17 (7–25) 8
The reversion point is defined as the dose of alcohol at which protection against total mortality i
asunaga et al. (22).
Abbreviations as in Table 2.abolism of the alcohol, medications, or both may be altered,
ffecting the therapeutic and adverse effects of the latter
34,35). A sensitive analysis with adjusted and nonadjusted
tudies for drug therapy (antiplatelet or oral anticoagulant
rugs) was not possible in our meta-analyses because of
imited available data.
ty in Cardiovascular Disease Patients
independent relationships using fixed (solid lines)
nce interval; 95% CI  upper value of confidence interval.
f Alcohol Intake and All-Causes Mortalityta-Analysis of Alcohol Intake and All-Causes Mortality
Reversion
Point*
(g/day)
Parameters of the Best-Fitted Model 
LogRR  1x  2x*log(x)
P for
Difference1 (SE) p Value 2 (SE) p Value
 0.001
8 –0.223 (0.114) 0.025 0.070 (0.039) 0.035
15 –0.251 (0.085)  0.001 0.085 (0.016)  0.001
 0.001
27 –0.147 (0.065) 0.012 0.033 (0.022) 0.070
24 –0.153 (0.047)  0.001 0.040 (0.017) 0.008
0.47
17 –0.172 (0.060) 0.002 0.050 (0.022) 0.010
27 –0.147 (0.082) 0.036 0.032 (0.027) 0.121
32 –0.167 (0.053)  0.001 0.038 (0.018) 0.020
24 –0.135 (0.056) 0.008 0.034 (0.020) 0.045
ger statistically significant at the 95% confidence level. †Excluding the curves from the study ofortali
from 7
onfidesis o: Me
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March 30, 2010:1339–47 Alcohol Consumption and Mortality in CVD Patientstudy limitations. A first limitation of our findings is that, in
he absence of randomized controlled trials, all the studies
ncluded in our meta-analyses were observational. Randomized
ontrolled trials offer a more solid answer than observational
tudies to many questions in medicine, mainly restricted,
owever, to the efficacy of drugs; however, controlled interven-
ion trials on diet in general and on alcohol in particular, are
ifficult and ethically questionable to perform (36,37).
Another limitation of our analyses is the small number of
tudies that could be included, especially when subanalyses
n interstudy heterogeneity were performed. In addition, an
ppropriate control for confounding variables was applied in
nly a few of the original studies.
An obvious weakness of our analyses—because of lack of
nformation from the original studies—is that in only a few
nstances was it possible to separate former drinkers from
ifetime abstainers within the nondrinking group. The
nclusion of former drinkers in the reference group who
ight have stopped because of health problems is question-
ble, and may explain, at least in part, the protective effect of
rinking in moderation (1,36). However, analysis of the 3
tudies (21,26,27) that formally excluded former drinkers
rom the no-alcohol category confirmed the relation be-
ween drinking in moderation and secondary prevention,
oo, as far as cardiovascular mortality was concerned.
Any meta-analysis can be plagued by publication bias,
Figure 4 Alcohol Consumption in Relation to All-Cause Mortalit
Pooled curves of relative risk of all-cause mortality and alcohol intake extracted fro
relationships using fixed (solid lines) and random (dotted lines) models. Abbreviaecause even high-quality studies reporting negative results mften are not submitted by investigators themselves or are
ot accepted for publication by editors. Thus, a formal
nalysis of publication bias was carried out: the funnel plots
ppeared to be symmetric for all the categories of alcohol
ntake, indicating the absence of publication bias in both our
eta-analyses.
Under-reporting of alcohol consumption would result in
tendency for relative risks to be biased toward the null
ypothesis, and this may have distorted the shape of the
urves and the apparent threshold for harm; however, both
eta-analyses showed significant association.
In the largest study included in our meta-analysis, The
hysicians Health Study (28), the protection associated
ith alcohol in moderation was greater for non-CVD than
or CVD deaths, an unexpected finding. In a subgroup
nalysis including the 2 studies only (26,28) for which data
n non-CVD mortality were available, we could confirm
uch a finding (data not shown). Thus, the possibility of
ncontrolled confounding by lifestyle, medicines, or other
actors among the light-to-moderate drinking patients cannot
e excluded, suggesting—at least in some studies—possible
election bias rather than a biological effect of alcohol (38).
onclusions
ur findings provide reasonable evidence that regular and
ardiovascular Disease Patients
dependent
s in Figure 3.y in C
m 7 in
tions aoderate alcohol intake is significantly associated with a
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Alcohol Consumption and Mortality in CVD Patients March 30, 2010:1339–47eduction in the incidence of secondary cardiovascular
vents and all-cause mortality. This conclusion extends to
VD patients what has been reported previously in appar-
ntly healthy people (1,11).
Cardiovascular patients should be informed that low-to-
oderate alcohol consumption (1 drink/day for women or
p to 2 drinks/day for men), should not be harmful to their
ealth. However, cardiovascular patients who do not regu-
arly consume alcohol should not be encouraged to start
rinking, owing to the lack of controlled intervention trials
n alcohol that are difficult and ethically questionable to
erform. No question, heavy or binge drinking can have
dverse health outcomes (10). If cardiovascular patients are
eavy drinkers, they must strongly be advised to abstain or
t least substantially reduce drinking.
Cardiologists should be aware that regular, moderate alcohol
onsumption, in the context of a healthy lifestyle (increased
hysical activity, no smoking), dietary habits (decreased dietary
at intake, high consumption of fruit and vegetables), and
dequate drug therapy, would put their patients at a level of
ardiovascular or mortality risk substantially lower than either
bstainers or heavy or binge drinkers.
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